What percentage of postmenopausal women with a 2 cm septated (separated) ovarian cyst develop ovarian mucinous adenocarcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Risk of Malignancy in 2 cm Septated Ovarian Cysts in Postmenopausal Women

A 2 cm septated ovarian cyst in a postmenopausal woman carries a very low risk of malignancy (<1%), and if the septations are thin (<3 mm) without solid components or papillary projections, this lesion would be classified as O-RADS 2 (almost certainly benign). 1

Risk Stratification Based on Cyst Characteristics

Size and Septation Features Matter Most

  • A 2 cm cyst with thin septations (<3 mm) is considered benign and falls into the O-RADS 2 category with <1% malignancy risk 1

  • The specific risk for septated cystic ovarian tumors without solid areas or papillary projections approaches 0% based on long-term surveillance data of 2,870 septated cysts where only 1 patient developed cancer in the contralateral ovary years later 2

  • In a study of 236 postmenopausal cysts (including those with isolated septa), no malignancy or borderline histology was observed even in cysts larger than 5 cm 3

Critical Features That Would Increase Risk

  • Irregular or thick septations (≥3 mm height) would elevate the lesion to O-RADS 3 (low risk, 1-<10% malignancy) 1

  • Any solid component or papillary projections ≥3 mm would immediately increase risk to O-RADS 4 (intermediate risk, 10-<50%) or higher 1

  • Ascites or peritoneal nodules would indicate O-RADS 5 (high risk, ≥50%) unless associated with a clearly benign lesion 1

Specific Context for Mucinous Adenocarcinoma

  • Mucinous ovarian neoplasms are uncommon malignancies, representing only 10-15% of all ovarian neoplasms, with 80% being benign and 16-17% borderline 4

  • Mucinous neoplasms typically present as large multiloculated masses (average 15-30 cm), not small 2 cm cysts 5, 4

  • A 2 cm septated cyst is highly unlikely to represent mucinous adenocarcinoma given the typical presentation pattern of these tumors 4

Management Recommendations

  • No immediate intervention is required for a 2 cm septated cyst with thin septations in a postmenopausal woman 1

  • Optional single follow-up ultrasound in 1 year is reasonable, though even this may not be necessary for such small lesions 1

  • Immediate gynecologic referral is warranted only if the cyst develops solid components, thick/irregular septations, papillary projections, or increases significantly in size 1

Common Pitfalls to Avoid

  • Do not confuse thin septations with solid components—use color Doppler to confirm absence of vascularity within septations 1

  • Do not recommend surgery based solely on postmenopausal status—even simple cysts up to 10 cm can be safely monitored in postmenopausal women 1

  • Do not over-rely on CA-125 levels as they can be elevated in benign conditions and have poor specificity 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of unilocular or multilocular cysts more than 5 centimeters in postmenopausal women.

European journal of obstetrics, gynecology, and reproductive biology, 2016

Research

Mucinous Neoplasms of the Ovary: Radiologic-Pathologic Correlation.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2019

Research

An Extremely Giant Ovarian Mucinous Cystadenoma.

The Gulf journal of oncology, 2019

Guideline

Management of Ovarian Cysts with Hyperandrogenism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.